NOX-driven ROS formation in cell transformation of FLT3-ITD-positive AML

被引:52
|
作者
Jayavelu, Ashok Kumar [1 ]
Moloney, Jennifer N. [2 ]
Boehmer, Frank-D. [1 ]
Cotter, Thomas G. [2 ]
机构
[1] Jena Univ Hosp, CMB, Inst Mol Cell Biol, Hans Knoll Str 2, D-07745 Jena, Germany
[2] Univ Coll Cork, Biosci Res Inst, Sch Biochem & Cell Biol, Tumour Biol Lab, Cork, Ireland
关键词
PROTEIN-TYROSINE PHOSPHATASES; ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATIONS; BCR-ABL; GENOMIC INSTABILITY; NADPH OXIDASES; DNA-DAMAGE; FLT3; ACTIVATION; MECHANISMS;
D O I
10.1016/j.exphem.2016.08.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In different types of myeloid leukemia, increased formation of reactive oxygen species (ROS) has been noted and associated with aspects of cell transformation, including the promotion of leukemic cell proliferation and migration, as well as DNA damage and accumulation of mutations. Work reviewed in this article has revealed the involvement of NADPH oxidase (NOX)-derived ROS downstream of oncogenic protein tyrosine kinases in both processes, and the related pathways have been partially identified. FMS-like tyrosine kinase 3 with internal tandem duplications (FLT3-ITD), an important oncoprotein in a subset of acute myeloid leuke-mias, causes activation of AKT and, subsequently, stabilization of p22(phox), a regulatory subunit for NOX1-4. This process is linked to ROS formation and DNA damage. Moreover, FLT3-ITD signaling through STAT5 enhances expression of NOX4, ROS formation, and inactivation of the protein tyrosine phosphatase DEP-1/PTPRJ, a negative regulator of FLT3 signaling, by reversible oxidation of its catalytic cysteine residue. Genetic inactivation of NOX4 restores DEP-1 activity and attenuates cell transformation by FLT3-ITD in vitro and in vivo. Future work is required to further explore these mechanisms and their causal involvement in leukemic cell transformation, which may result in the identification of novel candidate targets for therapy. Copyright (C) 2016 ISEH-International Society for Experimental Hematology. Published by Elsevier Inc.
引用
收藏
页码:1113 / 1122
页数:10
相关论文
共 50 条
  • [41] SRC is a signaling mediator in FLT3-ITD-but not in FLT3-TKD-positive AML
    Leischner, Hannes
    Albers, Corinna
    Grundler, Rebekka
    Razumovskaya, Elena
    Spiekermann, Karsten
    Bohlander, Stefan
    Ronnstrand, Lars
    Goetze, Katharina
    Peschel, Christian
    Duyster, Justus
    BLOOD, 2012, 119 (17) : 4026 - 4033
  • [42] Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML
    Wu, H.
    Hu, C.
    Wang, A.
    Weisberg, E. L.
    Wang, W.
    Chen, C.
    Zhao, Z.
    Yu, K.
    Liu, J.
    Wu, J.
    Nonami, A.
    Wang, L.
    Wang, B.
    Stone, R. M.
    Liu, S.
    Griffin, J. D.
    Liu, J.
    Liu, Q.
    LEUKEMIA, 2016, 30 (03) : 754 - 757
  • [43] Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML
    H Wu
    C Hu
    A Wang
    E L Weisberg
    W Wang
    C Chen
    Z Zhao
    K Yu
    J Liu
    J Wu
    A Nonami
    L Wang
    B Wang
    R M Stone
    S Liu
    J D Griffin
    J Liu
    Q Liu
    Leukemia, 2016, 30 : 754 - 757
  • [44] The Role of Mcl-1 Expression and Phosphorlyation in Resistance to Chemotherapy and Kinase Inhibitors in FLT3-ITD-Positive Acute Myeloid Leukemia (AML)
    Heidel, Florian H.
    Schulze-Bergkamen, Henning
    Vick, Binje
    Lipka, Daniel B.
    Mirea, Fian K.
    Urbanik, Toni
    Opferman, Joseph T.
    Fischer, Thomas
    BLOOD, 2008, 112 (11) : 88 - 88
  • [45] Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia
    Oran, Betul
    Cortes, Jorge
    Beitinjaneh, Amer
    Chen, Hsiang-Chun
    de Lima, Marcos
    Patel, Keyur
    Ravandi, Farhad
    Wang, Xuemei
    Brandt, Mark
    Andersson, Borje S.
    Ciurea, Stefan
    Santos, Fabio R.
    Silva, Leandro de Padua
    Shpall, Elizabeth J.
    Champlin, Richard E.
    Kantarjian, Hagop
    Borthakur, Gautam
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (07) : 1218 - 1226
  • [46] Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies
    Kasper, S.
    Breitenbuecher, F.
    Heidel, F.
    Hoffarth, S.
    Markova, B.
    Schuler, M.
    Fischer, T.
    BLOOD CANCER JOURNAL, 2012, 2 : e60 - e60
  • [47] Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies
    S Kasper
    F Breitenbuecher
    F Heidel
    S Hoffarth
    B Markova
    M Schuler
    T Fischer
    Blood Cancer Journal, 2012, 2 : e60 - e60
  • [48] Childhood Noonan Syndrome with FLT3-ITD-Positive Acute Myeloid Leukemia - A Case Report
    Sarashina, T.
    Goto, H.
    Miyagawa, N.
    Yokosuka, T.
    Fukuda, K.
    Iwasaki, F.
    Hamanoue, S.
    Shiomi, M.
    Goto, S.
    Azuma, H.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S442 - S443
  • [49] Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation with Sorafenib
    Sharma, Manish
    Ravandi, Farhad
    Bayraktar, Ulas Darda
    Chiattone, Alexandre
    Bashir, Qaiser
    Giralt, Sergio
    Chen, Julianne
    Qazilbash, Muzaffar
    Kebriaei, Partow
    Konopleva, Marina
    Andreeff, Michael
    Cortes, Jorge
    McCue, Deborah
    Kantarjian, Hagop
    Champlin, Richard E.
    de Lima, Marcos
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (12) : 1874 - 1877
  • [50] FLUVASTATIN CAN INCREASE APOPTOSIS INDUCED BY VALPROIC ACID AND ALL-TRANS-RETINOIC ACID IN FLT3-ITD-POSITIVE AML CELLS
    Zirm, E.
    Spies-Weisshart, B.
    Schnetzke, U.
    Hochhaus, A.
    Scholl, S.
    HAEMATOLOGICA, 2013, 98 : 508 - 508